US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist
  • 103.290
  • -2.670-2.52%
Trading Dec 19 10:13 ET
460.27BMarket Cap35.13P/E (TTM)

About Novo-Nordisk A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.

Company Profile

SymbolNVO
Company NameNovo-Nordisk A/S
Listing DateJul 9, 1981
Founded1931
CEOMr. Lars Fruergaard Jorgensen
MarketNYSE
Employees64319
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressNovo Allé 1
CityBagsv?rd
ProvinceCapital Region
CountryDenmark
Zip Code2880
Phone45-44-44-88-88

Company Executives

  • Name
  • Position
  • Salary
  • Lars Fruergaard Jorgensen
  • Chief Executive Officer and President
  • --
  • Marcus Schindler, PhD
  • Executive Vice President, Research and Early Development and Chief Scientific Officer
  • 23.60M
  • Karsten Munk Knudsen
  • Executive Vice President and Chief Financial Officer
  • 26.40M
  • Ludovic Helfgott
  • Executive Vice President, Rare Disease
  • 2.20M
  • Martin Holst Lange
  • Executive Vice President, Development
  • 23.40M
  • Doug Langa
  • Executive Vice President, North America Operations
  • 2.20M
  • Henrik Ehlers Wulff
  • Executive Vice President, Product Supply, Quality Assurance, Digital Data and IT
  • 25.90M
  • Maziar Mike Doustdar
  • Executive Vice President, International Operations
  • 2.20M
  • Camilla Sylvest
  • Executive Vice President, Commercial Strategy and Corporate Affairs
  • 23.40M
  • Henrik Poulsen
  • Vice Chairman of the Board
  • 2.40M
  • Helge Lund
  • Chairman of the Board
  • 3.90M
  • Thomas Rantzau
  • Director
  • 1.10M
  • Mette Bojer Jensen
  • Director
  • 1.30M
  • Elisabeth Dahl Christensen
  • Director
  • 1.10M
  • Liselotte Hyveled
  • Director
  • 1.10M
  • Kasim Kutay
  • Director
  • 1.30M
  • Dr. Sylvie Gregoire,Pharm.D.
  • Independent Director
  • 2.00M
  • Andreas Fibig
  • Independent Director
  • 1.40M
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 1.80M
  • Christina Law
  • Independent Director
  • 1.70M
  • Laurence Debroux
  • Independent Director
  • 2.10M
  • Tania Sabroe
  • Executive Vice President, People and Organisation
  • 2.20M
  • David Moore
  • Executive Vice President, Corporate Development
  • 2.20M
Heat List
US
Overall
Symbol
Price
% Chg

No Data